

aPROMISE

AI-enabled medical device software for quantitative PSMA PET/CT image analysis and standardized reporting for prostate cancer.

<https://example.com/1762583716452>

Overview

aPROMISE™ (Automated Prostate Molecular Imaging Standardized Evaluation) is a deep learning application and FDA-cleared, CE-marked medical device software developed to bring consistency, efficiency, and standardization to the assessment of PSMA PET/CT scans for prostate cancer. The software, which functions as a PACS platform, uses deep learning technology to automate the segmentation of anatomical regions (like the liver and aorta) in low-dose CT images. It then detects, localizes, and quantifies potential pathological lesions in the PSMA PET/CT images, significantly reducing the laborious task of manual quantification and improving inter-reader reproducibility.

Key Capabilities:

Quantitative Assessment: Generates quantitative total disease burden indices, such as the Quantitative PSMA Scan Index (PSI). These biomarkers support patient selection for treatment, including PSMA radioligand therapy (RLT), and automate the monitoring of response over time.

Efficiency: The system is designed to create a comprehensive, quantitative report in an average of approximately three minutes, enhancing clinical workflow.

Standardization: The platform supports standardized reporting, aligning with guidelines like E-PSMA.

Viewer: Includes a multi-modal viewer with PET, CT, Fusion, and MIP views, enabling healthcare professionals to review and verify the automated analysis.

Target Users & Use Cases:

Target Users: Nuclear Medicine Physicians, Radiologists, Oncologists, and Researchers.

Use Cases: Prostate cancer staging and diagnosis, monitoring treatment response, assessing quantitative tumor burden, and clinical trial analysis.

Key Features

- Deep Learning-Enabled Lesion Detection
- Automated Organ Segmentation (CT)
- Quantitative PSMA Scan Index (PSI)

- Multi-Modal Viewer (PET/CT/Fusion/MIP)
- Standardized E-PSMA Reporting
- Automated Quantification at Lesion Level (miT, miN, miMa)

Pricing

Model: enterprise

aPROMISE is specialized medical device software. Contact Syntermed or its partners (e.g., Lantheus, Siemens Healthineers) for enterprise licensing and pricing details.

Target Company Size: medium, enterprise

Integrations

Siemens Healthineers syngo.via, PACS Systems, DICOM

Compliance & Certifications

FDA 510(k) Cleared, CE Mark, HIPAA

This document was generated by IntuitionLabs.ai with the assistance of AI. While we strive for accuracy, please verify critical information independently.